Cargando…

Persistence of immunity to hepatitis B vaccine as infants, 17 years earlier

BACKGROUND: In Iran since 1992, hepatitis B vaccination was a part of the national vaccination program. Hepatitis B vaccination is effective in the epidemiology of hepatitis B. The aim of this study was to evaluate the long – term persistence of immunity. METHODS: This cross-sectional analytical stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Azarkar, Zohreh, Ebrahimzadeh, Azadeh, Sharifzadeh, Gholamreza, Ziaee, Masood, Fereidouni, Mohammad, Taheri, Fatemeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Babol University of Medical Sciences 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5912228/
https://www.ncbi.nlm.nih.gov/pubmed/29732038
http://dx.doi.org/10.22088/cjim.9.2.184
_version_ 1783316354681536512
author Azarkar, Zohreh
Ebrahimzadeh, Azadeh
Sharifzadeh, Gholamreza
Ziaee, Masood
Fereidouni, Mohammad
Taheri, Fatemeh
author_facet Azarkar, Zohreh
Ebrahimzadeh, Azadeh
Sharifzadeh, Gholamreza
Ziaee, Masood
Fereidouni, Mohammad
Taheri, Fatemeh
author_sort Azarkar, Zohreh
collection PubMed
description BACKGROUND: In Iran since 1992, hepatitis B vaccination was a part of the national vaccination program. Hepatitis B vaccination is effective in the epidemiology of hepatitis B. The aim of this study was to evaluate the long – term persistence of immunity. METHODS: This cross-sectional analytical study was conducted on children and adolescents aged between 6-18 years in Birjand, who received a three – dose hepatitis B vaccination in accordance with the national immunization program. No students were infected with hepatitis B. Antibody titer higher than10 IU/L was considered positive. RESULTS: A total of 530 patients (307 boys and 223 girls) were recruited for the study of which 44% had positive antibody titer (≥10 IU / L). The geometric concentration mean (GMCs) of antibody in subjects was 64.9±34.2, HBS antibody titer was positive in 40.4% of the boys and 59.6% of the girls. A significant difference in antibody titers was observed in terms of gender and according to the time elapsed since the last vaccination. Antibody titer in children older than 13 years had passed since their last vaccination and was significantly less than those children younger than thirteen years old had passed since their vaccination logistic regression analysis showed that the only predictive factor of anti-HBS low titer (<10 IU/L) is elapsed time of vaccination. CONCLUSIONS: Based on results of this study, hepatitis B vaccine has created a good level of protection in 44% of the adolescents after 17 years.
format Online
Article
Text
id pubmed-5912228
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Babol University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-59122282018-05-04 Persistence of immunity to hepatitis B vaccine as infants, 17 years earlier Azarkar, Zohreh Ebrahimzadeh, Azadeh Sharifzadeh, Gholamreza Ziaee, Masood Fereidouni, Mohammad Taheri, Fatemeh Caspian J Intern Med Original Article BACKGROUND: In Iran since 1992, hepatitis B vaccination was a part of the national vaccination program. Hepatitis B vaccination is effective in the epidemiology of hepatitis B. The aim of this study was to evaluate the long – term persistence of immunity. METHODS: This cross-sectional analytical study was conducted on children and adolescents aged between 6-18 years in Birjand, who received a three – dose hepatitis B vaccination in accordance with the national immunization program. No students were infected with hepatitis B. Antibody titer higher than10 IU/L was considered positive. RESULTS: A total of 530 patients (307 boys and 223 girls) were recruited for the study of which 44% had positive antibody titer (≥10 IU / L). The geometric concentration mean (GMCs) of antibody in subjects was 64.9±34.2, HBS antibody titer was positive in 40.4% of the boys and 59.6% of the girls. A significant difference in antibody titers was observed in terms of gender and according to the time elapsed since the last vaccination. Antibody titer in children older than 13 years had passed since their last vaccination and was significantly less than those children younger than thirteen years old had passed since their vaccination logistic regression analysis showed that the only predictive factor of anti-HBS low titer (<10 IU/L) is elapsed time of vaccination. CONCLUSIONS: Based on results of this study, hepatitis B vaccine has created a good level of protection in 44% of the adolescents after 17 years. Babol University of Medical Sciences 2018 /pmc/articles/PMC5912228/ /pubmed/29732038 http://dx.doi.org/10.22088/cjim.9.2.184 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Azarkar, Zohreh
Ebrahimzadeh, Azadeh
Sharifzadeh, Gholamreza
Ziaee, Masood
Fereidouni, Mohammad
Taheri, Fatemeh
Persistence of immunity to hepatitis B vaccine as infants, 17 years earlier
title Persistence of immunity to hepatitis B vaccine as infants, 17 years earlier
title_full Persistence of immunity to hepatitis B vaccine as infants, 17 years earlier
title_fullStr Persistence of immunity to hepatitis B vaccine as infants, 17 years earlier
title_full_unstemmed Persistence of immunity to hepatitis B vaccine as infants, 17 years earlier
title_short Persistence of immunity to hepatitis B vaccine as infants, 17 years earlier
title_sort persistence of immunity to hepatitis b vaccine as infants, 17 years earlier
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5912228/
https://www.ncbi.nlm.nih.gov/pubmed/29732038
http://dx.doi.org/10.22088/cjim.9.2.184
work_keys_str_mv AT azarkarzohreh persistenceofimmunitytohepatitisbvaccineasinfants17yearsearlier
AT ebrahimzadehazadeh persistenceofimmunitytohepatitisbvaccineasinfants17yearsearlier
AT sharifzadehgholamreza persistenceofimmunitytohepatitisbvaccineasinfants17yearsearlier
AT ziaeemasood persistenceofimmunitytohepatitisbvaccineasinfants17yearsearlier
AT fereidounimohammad persistenceofimmunitytohepatitisbvaccineasinfants17yearsearlier
AT taherifatemeh persistenceofimmunitytohepatitisbvaccineasinfants17yearsearlier